Neogenomics
Updated: December 19, 2025
Doug VanOort, CEO
Country: USA | Funding: $925.9M (+)
Founded: 1998
Website: https://neogenomics.com/
NeoGenomics is a reference laboratory for oncology research providing cancer testing services. It offers healthcare institutions a portfolio of over 500 solutions covering all major research methods, including single-gene molecular testing, immunohistochemistry, flow cytometry, fluorescence in situ hybridization, DNA and RNA next-generation sequencing and full-genome profiling. The company performs tissue analysis, liquid biopsy and blood testing to generate accurate and actionable data for personalized treatment. NeoGenomics also collaborates with pharmaceutical companies to develop new therapies for precision oncology. With one of the largest oncology databases, containing over 2 million unique patient profiles, the company optimizes clinical trial participant recruitment and treatment outcome assessment.
Founded: 1998
Website: https://neogenomics.com/
NeoGenomics is a reference laboratory for oncology research providing cancer testing services. It offers healthcare institutions a portfolio of over 500 solutions covering all major research methods, including single-gene molecular testing, immunohistochemistry, flow cytometry, fluorescence in situ hybridization, DNA and RNA next-generation sequencing and full-genome profiling. The company performs tissue analysis, liquid biopsy and blood testing to generate accurate and actionable data for personalized treatment. NeoGenomics also collaborates with pharmaceutical companies to develop new therapies for precision oncology. With one of the largest oncology databases, containing over 2 million unique patient profiles, the company optimizes clinical trial participant recruitment and treatment outcome assessment.
